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Abstract—Model identification allows to design different con-
trol strategies for antiangiogenic cancer therapy, and create
model-based treatment protocols. These model-based protocols
can be more effective than the current ones, since they provide
individual treatment for the patients. The aim of this paper is to
investigate C38 colon adenocarcinoma growth in three different
cases: (1) tumor growth without therapy, (2) tumor growth with
one Avastin dose for a 18-day therapy (10 mg/kg), (3) tumor
growth with one-tenth dose of control Avastin dose spread over
18 days. Parametric model identification was carried out for these
three cases and the relationship between the measured tumor
attributes (volume, mass and vascularization) was analyzed.
Effect of low-dose therapy was also examined.
I. INTRODUCTION
The key of scientific success in every field nowadays
depends on interdisciplinary design [1]. Medical treatment is
not an exception either, engineers and doctors have to work
together to find more effective solutions in healing. Beside
classical cancer treatments (surgical oncology, radiotherapy,
chemotherapy) a new approach have appeared called targeted
molecular therapies (TMTs). The main goal of these treatments
is to find a cancer specific mechanism which can be selectively
inhibited, thus the therapy do not have impact to healthy cells
(virtually do not have significant side effects). However finding
an appropriate medication is not enough, the effectiveness of
the treatment strongly depends on the drug administration
as well. Opposed to general protocols, precise, individual
treatment have to be developed - that can be executed by closed
loop controllers.
Antiangiogenic therapy is a type of TMTs, which inhibits
angiogenesis. Angiogenesis is the process of forming new
blood vessels; normally it occurs in the human body only at
specific times (e.g. in case of wound healing). Tumor cells can
break through this strict control and become able to form own
blood vessels, which is essential for survival after a certain
tumor size (1−2 mm diameter). In antiangiogenic therapy, the
patients get angiogenic inhibitor, which inhibits tumor-induced
angiogenesis, hence tumors will not be able to form new blood
vessels by sprouting from existing vessels. There are several
angiogenic inhibitors used in clinical practice, which act in
different molecular ways [2]. Widely used inhibitors in cancer
therapies are endostatin [3] and bevacizumab [4]. The paper is
focusing on the identification of tumor growth using the latter
bevacizumab (Avastin) therapy.
The paper is organized as follows. In Section II, we give
a brief overview of the phases of the experiment, and the
methods used in the experiment are described. Analysis of
the experimental results are shown is Section III, where three
topics are discussed: (1) C38 colon adenocarcinoma growth
identification with and without Avastin therapy, (2) Finding the
relationship between tumor volume, mass and vascularization,
(3) Finding the effective dosage for optimal therapy. The paper
ends in Section IV with the conclusion.
II. MATERIALS AND METHODS
This experiment is a collaboration between Physiologi-
cal Controls Group, Óbuda University (Budapest, Hungary)
and 1st Department of Pathology and Experimental Cancer
Research, Semmelweis University (Budapest, Hungary). The
identification procedure was supplied by several measurements
planned in a rigorous way. The aim of the experiment is to
create and validate a clinically relevant tumor growth model,
focusing on the effect of angiogenesis. Model identification
allows one to design different control strategies for antian-
giogenic cancer therapy, and create model-based treatment
protocols. These model-based protocols can be more effective
than the current ones, since they provide individual treatment
for the patients.
A. Overview of the phases
In Phase I, we have investigated tumor growth without
therapy with two types of mouse tumor. 12 mice were trans-
planted subcutaneously with C38 colon adenocarcinoma, and
11 mice were injected intramuscularly with B16 melanoma.
Results of this phase can be found in [5]. Phase II was the
toxicology investigation of the applied angiogenic inhibitor
(Avastin); there was no tumor implantation into mice in this
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Fig. 1. Detailed description and summary of the phases of the experiment.
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phase. We monitored the vital parameters of 4 mice, and we
could exclude any serious toxic effects or lethality regarding
the usage of Avastin. In Phase III, we have investigated C38
colon adenocarcinoma growth with Avastin therapy. In the
first subphase (Phase III/1), we have examined the optimal
administration of the angiogenic inhibitor, particularly with
regard to the quantity of the solvent (with 10 mice). In the
second subphase (Phase III/2), we created two groups. Control
group (6 mice) received Avastin in one dose according to the
protocol, case group (12 mice) received less dose every day
(see Section II.C).
Relevant phases according to this study can be found in Fig.
1.
B. Tumor implantation
A piece of C38 colon adenocarcinoma was transplanted
subcutaneously in the recipient animal.
C. Antiangiogenic therapy (Avastin administration)
As we have mentioned above, endostatin and bevacizumab
are typical angiogenic inhibitors in cancer treatment. Endo-
statin is an endogenous collagen, which inhibits cell migration,
cell proliferation and survival of endothelial cells [3]. In
contrast, bevacizumab (Avastin) [6] is an exogenous inhibitor,
which inhibits the biologic activity of human VEGF [7].
Recommended administration of Avastin is one 5−10 mg/kg
dose for 2−3 weeks [6]. We have administered 10 mg per kg
body weight intraperitoneally, which means 200 µg Avastin
per a mouse since the mass of the mice in the experiment was
20 g. This dose was used for a 18-day treatment.
In Phase I there was no Avastin administration. In Phase
III/2 the control group received 200 µg Avastin (with 455 µl
0.9% NaCl solution) in one dose intraperitoneally in the 3rd
day. In Phase III/2 the case group received one-tenth dose of
control dose intraperitoneally speared over 18 days. It means
that a case mouse received 1.11 µg Avastin (with 45 µl 0.9%
NaCl solution) every day for 18 days. Avastin administration
for the case group started at the 3rd day as well.
D. Tumor volume measurement
Tumor volume measurement cannot happen right after tu-
mor implantation. First, the subcutaneously transplanted piece
of tumor has to disintegrate, and after that the new tumor
colony (what we want to measure) can begin to grow from the
disintegrated tumor cells. This process takes 4-5 days. The first
measurement in Phase I occurred on the 5th day, in Phase III/2
it occured on the 4th day. Tumor diameters (width, length)
could be measured with a digital caliper during the experiment
because of the subcutaneous localization of the tumor. The
third dimension of the tumor (height) was approximated with
the length multiplied by 2/3. Assuming ellipsoid shape, the
tumor volume in mm3 was calculated by the formula:
V =
4
3
· pi · l
2
· w
2
· l
3
, (1)
where l is tumor length, w is tumor width, and h is tumor
height.
E. Sacrificing mice
In Phase III/2 mice were sacrificed after the 18-day treat-
ment, on the 21st day of the experiment. After sacrificing the
mice, the tumors were removed, and their volume and mass
were measured. After that, tumors were cut into two pieces:
one piece was stored in formalin, and the other piece was
freezed using liquid nitrogen.
F. Tumor sample processing
Tumor morphology was investigated using standard Haema-
toxylin Eosin (H&E) staining [8] with the samples stored in
formalin. The freezed samples were used to create frozen
sections [9] of the tumor. Tumor vasculation was stained
in vitro using CD31 antibody immunohistochemistry staining
[10] on frozen sections. After staining, fluorescence pictures
were done with confocal microscope and from these pictures
vascularization area was calculated by ImageJ [11] software.
III. ANALYSIS OF THE EXPERIMENTAL RESULTS
A. Experimental data
In Phase I 12 mice were implanted with C38 colon adeno-
carcinoma. One of them died on the 18th day, and another
one on the 23th day. Thus 10 mice were sacrificed on the
24th day of the experiment. In Phase III/2 the control group
contained 6 mice, the case group contained 12 mice; all mice
were implanted with C38 colon adenocarcinoma. No mice died
during the experiment, therefore 6 contol and 12 case mice
were sacrificed after the 18-day Avastin treatment, on the 21th
day of the experiment.
B. C38 colon adenocarcinoma growth identification with and
without Avastin therapy
In tumor growth there are two main processes which take
place. The first process, actually the engine of tumor growth
is the vascular growth; new blood vessels are indispensable
for the tumor to pick up enough nutrients and oxygen. With
the support of vasculature, tumor mass growth can occur as
the second process. Taking into account these two dynamics
behind tumor growth, we are seeking for a second order system
for identification. The second order system has two exponen-
tial functions in its response, thus parametric identification was
carried out by fitting a curve with two exponential functions.
The curve was fitted to the average tumor volume of each mice
at the measurement points (days). Since the system of tumor
growth is unstable, identification of the system is difficult.
Result of the parametric identification in the case of C38
colon adenocarcinoma growth without antiangiogenic therapy
(Phase I) was:
ypI(t) = 29020 · exp(0.29788t)− 29010 · exp(0.29789t)
(2)
Time constants of the system are T1 = 3.3570 days, T2 =
3.3568 days.
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Fig. 2. Comparison of C38 colon adenocarcinoma growth in three different cases. In Phase I, tumor growth was investigated without antiangiogenic therapy;
in Phase III/2, control group members received one 200 µg Avastin dose for a 18-day therapy; in Phase III/2, case group members received 1.11 µg Avastin
every day for 18 days. The first row shows the second order exponential curve fitting for the average of measurement points; in the second row one can see
the impulse response of the identificated systems; while the third row shows the poles and zeros of the identificated systems.
Result of the parametric identification in the case of C38
colon adenocarcinoma growth with Avastin therapy (Phase
III/2), control group was:
ypIII/2control(t) =
2.28171 · 106 · exp(0.114578t)
+2.28170 · 106 · exp(0.114579t)
(3)
Time constants of the system are T1 = 8.7277 days, T2 =
8.7276 days.
Result of the parametric identification in the case of C38
colon adenocarcinoma growth with Avastin therapy (Phase
III/2), case group was:
ypIII/2case(t) =
1.37190 · 106 · exp(0.07045t)
−1.37196 · 106 · exp(0.07044t)
(4)
Time constants of the system are T1 = 14.1935 days, T2 =
14.1950 days.
Comparison of the results in the three different cases can be
found in Fig. 2. The coefficients of the exponential functions
are positive in every cases, reflecting the unstability of the
system (as it is required from a tumor growth model). As
one can see, in every cases parametric identification resulted
in almost identical time constants; however, the usage of two
exponential function is not pointless. From the physiological
point of view there are two concrete dynamics which have
to be modeled. The engineering interpretation of this result
is an integrator series, which means that the change of the
first state variable (which is also the output of the system,
that is the tumor volume) depends on the second state vari-
able (vascularization). In addition, the change of the second
state variable depends on the input. Both interpretations are
physiologically correct.
From the fitted curves, transfer function of the models can
be calculated.
Transfer function of C38 colon adenocarcinoma growth
without antiangiogenic therapy (Phase I) resulted in:
WpI(t) =
8.715s− 2.895
s2 − 0.5958s+ 0.08874 (5)
Poles of the system are ppI,1 = 0.29788, ppI,1 = 0.29789.
Transfer function of C38 colon adenocarcinoma growth with
Avastin therapy (Phase III/2), control group resulted in:
WpIII/2control(t) =
−12.34s+ 3.764
s2 − 0.2292s+ 0.01313 (6)
Poles of the system are ppIII/2control,1 = 0.11457,
ppIII/2control,2 = 0.11458.
Transfer function of C38 colon adenocarcinoma growth with
Avastin therapy (Phase III/2), case group resulted in:
WpIII/2case(t) =
−61.79s+ 14.33
s2 − 0.1409s+ 0.004963 (7)
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Fig. 3. Linear regression analysis for tumor volume – tumor mass, tumor volume – vascularization, and tumor mass – vascularization pairs. In Phase
I, tumor growth was investigated without antiangiogenic therapy; in Phase III/2, control group members received one 200 µg Avastin dose for a 18-day
therapy; in Phase III/2, case group members received 1.11 µg Avastin every day for 18 days. R is the Pearson correlation coefficient, R2 is the coefficient
of determination, p is the ANOVA significance value (level of significance is p = 0.05).
Poles of the system are ppIII/2case,1 = 0.07044,
ppIII/2case,2 = 0.07045.
From the poles of the systems (third row of Fig. 2) we
can conclude that each system is unstable. To verify the
goodness of the created transfer functions, we plotted the
impulse response of each transfer function (second row of Fig.
2), which shows quite similar result to the curve fitting (first
row of Fig. 2).
C. Finding the relationship between tumor volume, mass and
vascularization
Three attributes of the lethal sized tumor were measured:
tumor volume, tumor mass and vascularization. Relationship
between these tumor attributes was investigated with linear
regression analysis [12]. To decide wether the relationship is
significant or not between two variables, we used the following
statistics. Pearson correlation coefficient (R) describes strength
of the correlation (linear dependence) between the variables.
Coefficient of determination (R2) tells how many percent of
the variability in a data can be explained by the given statistical
model (which is a linear model in every investigated cases).
Using Analysis of Variance (ANOVA) test [13] we can decide
that the regression analysis is valid or not (level of significance
was chosen to p = 0.05).
Results are summarized in Fig. 3. As one can see, the
relationship between tumor volume and mass is significant and
positive in all cases, which means that the larger the volume,
the higher the mass. The third attribute, tumor vascularization
shows interesting results.
On the one hand, vascularization does not have signifi-
cant relationship with volume or mass in neither cases. The
physiological explanation for this result is that in C38 colon
adenocarcinoma there are several necrotic regions, thus the
whole mass contains relatively few viable cells and vessels
[14].
On the other hand in the case of Phase III/2 control group,
tumor volume and tumor mass both have negative correla-
tion with vascularization, however these relationships are not
significant (tumor mass – vascularization have near-significant
relationship). The possible explanation is the following [15]. In
the case when angiogenesis occurs according to normal trigger,
pro- and antiangiogenic factors have balance, consequently the
newly formed vessels are normal with effective blood supply.
However, in the case of tumor-induced angiogenesis, there is
an extra proangiogenic factor produce due to hurried vessel
forming, which result in abnormal vessels (high vascular per-
meability, poor perfusion) with inefficient blood supply. High
interstitial fluid pressure can compress the vessels; thereafter
abnormal tumor growth may continue, however delivery of
therapeutic agents to the tumor is obstructed. Therefore, first
abnormal vessels have to be normalized with the balance of
pro- and antiangiogenic factors, thus vascular network can be
restored. This creates the possibility of efficient therapeutic
agent use.
In the case of Phase III/2 control group, mice received a
big dose of Avastin according to the protocol. This resulted
in a sudden preponderance of anti-factors; however, due to
abnormal vessel network, the utilization of the antiangiogenic
molecules was not effective. Despite the high dose, only a
small fraction could be used. That is why larger tumors had
fewer viable vessels in control group. In contrast in the case of
Phase III/2 case group, mice received a small dose of Avastin,
which – with the continuous, slow increase of antiangiogenic
factors – enabled the normalization of blood vessels [16];
hence Avastin could be used more efficiently.
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D. Finding the effective dosage for optimal therapy
To compare the results of the three investigated cases (Phase
I, Phase III/2 control group, Phase III/2 case group) we
used statistical analysis. Tumor volume values, which were
measured on the 21st day in each phase, were compared.
Before the usage of any statistical tests, one have to examine
the normality and homogeneity of variance (homoscedasticity)
of the distributions. Normality was investigated with one-
sample Kolmogorov-Smirnov test [17]; it was found that each
sample has normal distribution (ppI = 0.966, ppIII/2control =
0.999, ppIII/2case = 0.608). Homogenity of variance was
examined with Levene’s test [18]; the sample variances are
equal (p = 0.266).
After confirming normality and homoscedasticity, paramet-
ric statistical analysis can be used. With Analysis of Variance
(ANOVA) test [13] more than two samples are comparable.
ANOVA test was resulted in p = 0.038 value, which means
that we have to reject the null hypothesis according to which
there are no differences between the means of the samples
(using a p = 0.05 level of significance). To find those
samples, which have significantly differnet means, Tukey’s
honest significant difference (HSD) test was used as post hoc
test. The results are the following. Phase I and Phase III/2
control group are significantly different (p = 0.034), which
means that Avastin – administered according to the protocol
– is an effective drug to reduce tumor volume. Phase III/2
control group and Phase III/2 case group are not significantly
different (p = 0.416), however Phase I and Phase III/2 case
group are not significantly different (p = 0.227) either. This
means that the effectiveness of the "continuous" (daily) 1/180
dosage (1.11 µg relative to 200 µg) is comparable with the
effectiveness of one large dose.
IV. CONCLUSION
In our experiment three different cases were investigated.
In Phase I, C38 colon adenocarcinoma growth was examined
without antiangiogenic therapy; in Phase III/2, control group
members received one 200 µg Avastin dose for a 18-day
therapy; in Phase III/2, case group members received 1.11
µg Avastin every day for 18 days (one-tenth dose of control
dose intraperitoneally spread over 18 days). Parametric model
identification was carried out for these three cases. Relation-
ship between the measured tumor attributes (volume, mass and
vascularization) was also analyzed.
We have found that the effectiveness of the "continuous"
(daily) 1/180 dosage (1.11 µg relative to 200 µg) is comparable
with the effectiveness of one large dose. In addition, this is
a short-term result (18-day treatment); predicted long-term
results are more better, since the identified model for case
group has slower dynamics (time constants of the system are
approx. 14 days) than the identified model for control group
(time constants of the system are approx. 8 days). Taking into
account the physiological aspects as well, on the one hand,
daily small dosage is better than one large dose, because
it enables the normalization of blood vessels [16]; hence
Avastin could be used more efficiently; on the other hand, if
antiangiogenesis is persistent, it can completely destroy the
vascular network, which leads to tumor necrosis (death of
tumor) [15]. Furthermore, it does not have to be ignored that a
considerably lower dose have considerably lower side-effects
(or virtually nothing).
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